CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy

Junshik Hong, Sanghui Park, Jinny Park, Seung Jun Jang, Hee Kyung Ahn, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy, immunohistochemistry for CD99/ CD10/BCL-2/BCL-6/MUM-1 was performed on nodal DLBCL specimens from 70 patients. Patients were classified as either germinal center B-cell (GCB) subtype or non- GCB subtype according to the Muris algorithm. A superior 2-year event-free survival (EFS) was observed in patients with the GCB subgroup, compared to those with the non- GCB subgroup (p=0.034). The distribution of CD99 expression (29 patients; 41.4 %) did not show deviation according to subtype and was not prognostic for survival in the entire patient population. Among patients with the GCB subgroup, better EFS and overall survival (OS) were observed in CD99+ patients, compared to CD99? patients. Conversely, among patients with the non-GCB subgroup, inferior EFS and OS were reported in CD99+ patients. Superior 2-year EFS (p=0.004) and 2-year OS (p00.003) were observed in patients with GCB/CD99+ and non-GCB/ CD99? compared to the others, and the combination classification was found to be an independent prognostic factor.

Original languageEnglish
Pages (from-to)1897-1906
Number of pages10
JournalAnnals of Hematology
Volume91
Issue number12
DOIs
StatePublished - Dec 2012

Bibliographical note

Funding Information:
Acknowledgments This work was supported by the Ewha Womans University Research Grant of 2012.

Keywords

  • CD99
  • Diffuse large B-cell lymphoma
  • Immunohistochemistry
  • Prognosis

Fingerprint

Dive into the research topics of 'CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy'. Together they form a unique fingerprint.

Cite this